CN114650814A - 极长链多不饱和脂肪酸、类延长素羟基化衍生物和使用方法 - Google Patents

极长链多不饱和脂肪酸、类延长素羟基化衍生物和使用方法 Download PDF

Info

Publication number
CN114650814A
CN114650814A CN202080072552.7A CN202080072552A CN114650814A CN 114650814 A CN114650814 A CN 114650814A CN 202080072552 A CN202080072552 A CN 202080072552A CN 114650814 A CN114650814 A CN 114650814A
Authority
CN
China
Prior art keywords
elongin
cells
elv
carbon
vlc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080072552.7A
Other languages
English (en)
Chinese (zh)
Inventor
里卡多·帕拉西奥斯·佩莱兹
N·G·巴赞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Luis Anna State University Monitoring Committee College Of Agriculture And Mechanical Engineering
Original Assignee
Luis Anna State University Monitoring Committee College Of Agriculture And Mechanical Engineering
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luis Anna State University Monitoring Committee College Of Agriculture And Mechanical Engineering filed Critical Luis Anna State University Monitoring Committee College Of Agriculture And Mechanical Engineering
Publication of CN114650814A publication Critical patent/CN114650814A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080072552.7A 2019-09-04 2020-09-04 极长链多不饱和脂肪酸、类延长素羟基化衍生物和使用方法 Pending CN114650814A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962895737P 2019-09-04 2019-09-04
US62/895,737 2019-09-04
US201962923770P 2019-10-21 2019-10-21
US62/923,770 2019-10-21
US201962924359P 2019-10-22 2019-10-22
US62/924,359 2019-10-22
US202062964995P 2020-01-23 2020-01-23
US62/964,995 2020-01-23
PCT/US2020/049541 WO2021046448A1 (en) 2019-09-04 2020-09-04 Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use

Publications (1)

Publication Number Publication Date
CN114650814A true CN114650814A (zh) 2022-06-21

Family

ID=74853054

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080072552.7A Pending CN114650814A (zh) 2019-09-04 2020-09-04 极长链多不饱和脂肪酸、类延长素羟基化衍生物和使用方法

Country Status (9)

Country Link
US (1) US20220339134A1 (enExample)
EP (1) EP4025201A4 (enExample)
JP (2) JP2022547080A (enExample)
CN (1) CN114650814A (enExample)
AU (1) AU2020343029A1 (enExample)
BR (1) BR112022003985A2 (enExample)
CA (1) CA3153088A1 (enExample)
MX (1) MX2022002687A (enExample)
WO (1) WO2021046448A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022056311A1 (en) * 2020-09-10 2022-03-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
CN118524834A (zh) * 2021-12-03 2024-08-20 株式会社日水 氧化应激缓和方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107428652A (zh) * 2015-02-09 2017-12-01 路易斯安娜州立大学监测委员会农业和机械学院 用于治疗炎性疾病、退行性疾病和神经退行性疾病的化合物、组合物和方法
WO2018175288A1 (en) * 2017-03-20 2018-09-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037180A1 (en) * 2008-10-03 2010-04-08 Glycan Biosciences Pty Ltd Anionic oligosaccharide conjugates
US20130190399A1 (en) * 2009-10-31 2013-07-25 Martek Biosciences Corporation Synthesis and use of omega-3 and omega 6 very long chain polyunsaturated fatty acids (VLC-PUFA)
US20170014365A1 (en) * 2015-07-14 2017-01-19 The Board Of Regents Of The University Of Oklahoma Compositions Containing Very Long Chain Saturated Fatty Acids and Methods of Use
WO2017077528A2 (en) * 2015-11-02 2017-05-11 Salzman Lovelace Investments, Ltd. Methods and pharmaceutical compositions for treatment of lung inflammation
US20220226270A1 (en) * 2019-04-04 2022-07-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107428652A (zh) * 2015-02-09 2017-12-01 路易斯安娜州立大学监测委员会农业和机械学院 用于治疗炎性疾病、退行性疾病和神经退行性疾病的化合物、组合物和方法
WO2018175288A1 (en) * 2017-03-20 2018-09-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAROLINE KRAUSE 等: "The role of interleukin-1 in allergy-related disorders", 《CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY》, vol. 12, no. 5, pages 477 - 484 *
MOISES A. CALDERON 等: "A comparison of cytokine release from epithelial cells cultured from nasal biopsy specimens of atopic patients with and without rhinitis and nonatopic subjects without rhinitis", 《J ALLERGY CLINIMMUNOL》, vol. 99, no. 1, pages 65 - 76, XP005898988, DOI: 10.1016/S0091-6749(97)70302-6 *

Also Published As

Publication number Publication date
JP2025143368A (ja) 2025-10-01
MX2022002687A (es) 2022-06-16
EP4025201A4 (en) 2023-08-30
JP2022547080A (ja) 2022-11-10
BR112022003985A2 (pt) 2022-05-24
EP4025201A1 (en) 2022-07-13
US20220339134A1 (en) 2022-10-27
CA3153088A1 (en) 2021-03-11
WO2021046448A1 (en) 2021-03-11
AU2020343029A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
JP2025143368A (ja) 超長鎖多価不飽和脂肪酸であるエロバノイドヒドロキシル化誘導体、および使用方法
US20170087195A1 (en) Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria
JP2019511495A (ja) ＧＳＫ３β阻害薬チデグルシブによるＣＤＫＬ５障害の治療
JP2011126918A (ja) 神経系の障害の処置
WO2013070879A1 (en) Methods for treating spinal cord injury with lpa receptor antagonists
JP2020514391A (ja) 超長鎖多価不飽和脂肪酸、エロバノイドヒドロキシル化誘導体、および使用方法
JP7850416B2 (ja) 細胞外小胞に含まれるｅｎａｍｐｔの産生および使用
KR20170012555A (ko) 신경 질환 및 대뇌 상해의 치료를 위한 조성물 및 방법
CA2931345A1 (en) Use of indolyl and idolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits
US20240075004A1 (en) Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
AU2021283886A1 (en) Dihomo-gamma linolenic acid (DGLA) is a novel senolytic
JP6928450B2 (ja) エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法
US12329756B2 (en) Regulation of eIF4E activity for migraine therapy
US20240000853A1 (en) Lipocalin-type prostaglandin d2 synthase production promoting agent
JP5788907B2 (ja) 疾患の治療に使用される化合物
JP2021512086A (ja) アルツハイマー病の予防又は治療方法
JP2023541886A (ja) 超長鎖多価不飽和脂肪酸、エロバノイドヒドロキシル化誘導体、及び使用方法
WO2022217035A1 (en) Activators of integrated stress response pathway for protection against ferroptosis
JP7249433B2 (ja) 蜂毒抽出物を有効成分として含有する神経炎症疾患の予防または治療用組成物
TWI681774B (zh) 一種縞瓣屬二甲亞碸萃取物或級分之新穎用途
KR20220024145A (ko) 뇌전증 발생의 예방 및/또는 치료를 위한 마리마스타트의 용도
KR102374047B1 (ko) N,N′-디아세틸-p-페닐렌디아민 화합물을 유효성분으로 포함하는 알츠하이머병 예방, 개선 또는 치료용 조성물
KR20240001620A (ko) hsa-miR-4517 발현 촉진제를 포함하는 천식 예방, 치료, 또는 개선용 조성물 및 마이크로코커스 루테우스 유래 소포를 이용한 천식 진단방법
HK40031535B (en) Lipocalin-type prostaglandin d2 synthase production accelerating agent
HK40031535A (en) Lipocalin-type prostaglandin d2 synthase production accelerating agent

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination